Premium
Role of CYP2D6 polymorphism in predicting liver fibrosis progression rate in Caucasian patients with chronic hepatitis C
Author(s) -
Fishman Sigal,
Lurie Yoav,
Peretz Hava,
Morad Tova,
Grynberg Elisheva,
Blendis Laurie M,
Leshno Moshe,
Brazowski Eli,
Rosner Guy,
Halpern Zamir,
Oren Ran
Publication year - 2006
Publication title -
liver international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.873
H-Index - 110
eISSN - 1478-3231
pISSN - 1478-3223
DOI - 10.1111/j.1478-3231.2005.01236.x
Subject(s) - chronic hepatitis , medicine , gastroenterology , liver fibrosis , cyp2d6 , fibrosis , immunology , cytochrome p450 , virus , metabolism
Objective: Previous studies have demonstrated that CYP2D6 polymorphism is associated with liver cirrhosis. The aim of the present study was to find out whether CYP2D6 * 4, the poor metabolizer allele can predict fibrosis progression rate. Methods: Seventy‐five Caucasian patients with chronic hepatitis C infection were recruited. They were divided into two groups, ‘fast fibrosers’ and ‘slow fibrosers’, according to Poynard's fibrosis progression curves. Sixty‐two patients underwent liver biopsy. Twenty healthy neonates were included as control population. DNA was extracted from peripheral blood and CYP2D6 * 4 was tested by polymer chain reaction using fluorescent hybridization probes in a lightCycler instrument. Results: Forty‐two patients were classified as ‘fast fibrosers’ and 33 patients as ‘slow fibrosers’. The frequency of CYP2D6 * 4 allele in the ‘fast fibrosers’ (34.5%) was significantly higher compared with the ‘slow fibrosers’ (15%) ( P ‐value=0.007). There was no significant difference between the frequency of CYP2D6 * 4 in the ‘slow fibrosers’ (15%) compared with the controls (12.5%). Carrier state of CYP2D6 * 4 was the only covariate that was significantly positively correlated with fast progression to cirrhosis (odds ratio=6.5, P =0.01). Conclusion: This study indicates for the first time that CYP2D6 genotype might be a significant predictor of liver fibrosis progression rate in chronic hepatitis C patients.